Table 3 Comparison of patients characteristics according to glucometabolic state
NGT n = 11 | Prediabetes n = 31 | Diabetes n = 14 | p | |
|---|---|---|---|---|
Age (years) | 64 ± 17 | 69 ± 11 | 70 ± 11 | .58 |
Sex (% male) | 91 | 58 | 64 | .15 |
BMI (kg/m2) | 25.1 ± 3.7 | 27.6 ± 5.5 | 29.9 ± 9.7 | .39 |
Aetiology (% IHD) | 27 | 32 | 57 | .22 |
NYHA class (% I-II-III) | 55-36-9 | 23-48-29 | 21-57-21 | .34 |
LVEF (%) | 43 ± 13 | 42 ± 12 | 40 ± 12 | .71 |
E/E’ (n = 5, n = 13, n = 7) | 21.4 ± 19.4 | 21.2 ± 11.0 | 15.0 ± 8.7 | .33 |
ACE-inhibitor or AIIA (%) | 100 | 74 | 86 | .16 |
% optimal daily dosage | 73 ± 26 | 96 ± 32 | 88 ± 61 | .15 |
Selective β-blocker (%) | 73 | 77 | 86 | .75 |
% optimal daily dosage | 41 ± 17 | 52 ± 27 | 52 ± 25 | .56 |
Non-selective β -blocker (%) | 18 | 13 | 7 | .75 |
% optimal daily dosage | 150 ± 71 | 137 ± 75 | 50 ± 0 | .40 |
Diuretic (%) | 64 | 84 | 71 | .32 |
% usual daily dosage | 113 ± 67 | 103 ± 73 | 129 ± 106 | .75 |
BNP (pg/mL) | 167 ± 120 | 177 ± 207 | 293 ± 383 | .39 |
HbA1c (%) | 5.3 ± 0.2 | 5.7 ± 0.3 | 5.9 ± 0.3 | .01 * |
Total cholesterol (mg/dL) | 176 ± 39 | 173 ± 45 | 169 ± 53 | .81 |
HDL cholesterol (mg/dL) | 43 ± 11 | 50 ± 15 | 49 ± 15 | .39 |
LDL cholesterol (mg/dL) | 107 ± 29 | 93 ± 32 | 88 ± 42 | .25 |
Triglycerides (mg/dL) | 131 ± 35 | 159 ± 101 | 160 ± 88 | .94 |
Body weight (kg) | 76.5 ± 15.8 | 76.5 ± 16.5 | 82.9 ± 30.0 | .10 |
Fat mass (%) | 31.1 ± 6.9 | 35.2 ± 9.1 | 34.8 ± 9.2 | .52 |
Lean mass (kg) | 52.2 ± 9.3 | 49.3 ± 9.7 | 52.2 ± 12.4 | .62 |
Fat trunk/fat limb ratio | 1.28 ± 0.39 | 1.39 ± 0.26 | 1.63 ± 0.35 | .03** |
Extension strength (Nm/kg) | ||||
45° | 16.8 ± 6.1 | 13.9 ± 2.9 | 13.7 ± 5.1 | .32 |
90° | 16.6 ± 3.0 | 15.4 ± 4.1 | 15.3 ± 6.4 | .58 |
Flexion strength (Nm/kg) | ||||
45° | 9.0 ± 2.8 | 8.2 ± 2.2 | 7.8 ± 3.4 | .89 |
90° | 7.5 ± 2.2 | 6.7 ± 1.9 | 6.2 ± 2.4 | .60 |
Self-reported physical activity (METminutes/day) | 1921 (533-4313) | 1872 (1789-4047) | 1219 (664-5686) | .73 |